TY - JOUR
T1 - Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma
AU - Robetorye, Ryan S.
AU - Ramsower, Colleen A.
AU - Rosenthal, Allison C.
AU - Yip, Tameson K.
AU - Wendel Spiczka, Amy J.
AU - Glinsmann-Gibson, Betty J.
AU - Rimsza, Lisa M.
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/3/11
Y1 - 2019/3/11
N2 - Diffuse large B cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including germinal center B cell type, activated B cell type, and unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression-profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.
AB - Diffuse large B cell lymphomas (DLBCL) represent a clinically heterogeneous group of lymphomas that are classified together based on similarities in morphology and immunophenotype. Gene expression profiling further classifies DLBCL into distinct molecular subgroups based on cell-of-origin (COO), including germinal center B cell type, activated B cell type, and unclassified type. COO assignment of DLBCL has important biological and prognostic significance, as well as emerging therapeutic implications. Herein, we describe the first clinical validation of a digital gene expression-profiling assay (Lymph2Cx) to perform COO assignment in the routine work-up of DLBCL using formalin-fixed paraffin-embedded (FFPE) tissue sections and describe the results of 90 consecutive DLBCL cases analyzed prospectively by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA)-certified clinical molecular diagnostics laboratory.
KW - Cell-of-origin
KW - Diffuse large B cell lymphoma
KW - Gene expression profiling
KW - Lymph2Cx
UR - http://www.scopus.com/inward/record.url?scp=85064173588&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064173588&partnerID=8YFLogxK
U2 - 10.1007/s12308-019-00344-0
DO - 10.1007/s12308-019-00344-0
M3 - Article
AN - SCOPUS:85064173588
SN - 1865-5785
VL - 12
SP - 3
EP - 10
JO - Journal of Hematopathology
JF - Journal of Hematopathology
IS - 1
ER -